Theravance Biopharma (TBPH) Price & Analysis

Compare

343 Followers

TBPH Stock Chart & Stats

$17.61

-$0.06(-0.65%)

At close: Jan 08 4:00 PM EST

$17.61

-$0.06(-0.65%)

Day’s Range― - ―

52-Week Range$7.90 - $20.33

Previous CloseN/A

Volume28.33K

Average Volume (3M)519.95K

Market Cap

$918.18M

Enterprise Value$472.77M

Total Cash (Recent Filing)$329.68M

Total Debt (Recent Filing)$44.59M

Price to Earnings (P/E)31.7

Beta0.95

Next Earnings

Mar 02, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.07

Shares Outstanding50,672,432

10 Day Avg. Volume470,146

30 Day Avg. Volume519,947

Financial Highlights & Ratios

PEG Ratio-0.54

Price to Book (P/B)2.62

Price to Sales (P/S)7.14

P/FCF Ratio-38.73

Enterprise Value/Market Cap0.51

Enterprise Value/Revenue5.89

Enterprise Value/Gross Profit9.40

Enterprise Value/Ebitda-18.29

Forecast

1Y Price Target

$28.33

Price Target Upside60.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial OpportunityAmpreloxetine's commercial opportunity looks appealing, with physicians and payors recognizing the unmet need and potential impact of ampreloxetine.

Market PositioningAmpreloxetine looks well positioned to command preferential market positioning if the Phase 3 CYPRESS trial achieves success.

Potential Market ShareAmpreloxetine could easily capture substantial market share, pending positive CYPRESS results, a consistent safety profile, and approval.

Bears Say

Safety ConcernsApproximately 50% of patients develop treatment limiting supine hypertension.

Treatment EfficacyCurrently available treatment options fall short, with up to 70% of patients being inadequately controlled.

Trial RecruitmentSlow trial recruitment attributed to logistical hurdles, not patient scarcity.

Theravance Biopharma News

Theravance Biopharma initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Theravance Biopharma (TBPH) with an Outperform rating and $27 price target The firm sees...

9d ago

TBPH

These 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

13d ago

GPCR

TBPH

Theravance Biopharma price target raised to $40 from $25 at BTIG

BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $40 from $25 and keeps a Buy...

16d ago

TBPH

Theravance Biopharma management to meet virtually with BTIG

Virtual Meeting to be held on November 24 hosted by BTIG. Published first on TheFly – the ultimate...

25d ago

TBPH

Theravance Biopharma’s Ampreloxetine: A Promising Candidate for Neurogenic Orthostatic Hypotension with Strong Market Potential

Analyst Julian Harrison of BTIG maintained a Buy rating on Theravance Biopharma, retaining the price target of $40.00....

2d ago

TBPH

Theravance Biopharma’s Ampreloxetine: A Promising Solution for MSA with Strategic Market Positioning

Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Theravance Biopharma. The associated price target is...

2d ago

TBPH

Theravance Biopharma’s Ampreloxetine: A Promising Treatment for Neurogenic Orthostatic Hypotension with Strong Commercial Prospects

Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Theravance Biopharma, retaining the price target of...

3d ago

TBPH

Theravance Biopharma Hosts Key Opinion Leader Event

The latest announcement is out from Theravance Biopharma ( ($TBPH) ). On December 8, 2025, Theravance Biopharma held...

4d ago

TBPH

Theravance Biopharma’s Earnings Call Highlights Robust Growth

Theravance Biopharma (($TBPH)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

TBPH

Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Theravance Biopharma (TBPH) to $20 from $15...

1M ago

TBPH

Theravance Biopharma: Hold Rating Amid Steady Growth and Pipeline Uncertainty

Marc Frahm, an analyst from TD Cowen, maintained the Hold rating on Theravance Biopharma. The associated price target...

1M ago

TBPH

Theravance Biopharma Reports Strong Q3 2025 Results

Theravance Biopharma ( ($TBPH) ) has released its Q3 earnings. Here is a breakdown of the information Theravance...

1M ago

TBPH

Theravance Biopharma reports Q3 EPS 7c, consensus (5c)

Reports Q3 revenue $20.0M, consensus $19.89M. “Theravance delivered strong results in the third quarter, highlighted by record YUPELRI...

1M ago

TBPH

TBPH Upcoming Earnings Report: What to Expect?

Theravance Biopharma (TBPH) is scheduled to report 3rd quarter earnings on 11/10/2025, after the market closes. Regarding Q3...

1M ago

TBPH

TBPH FAQ

What was Theravance Biopharma’s price range in the past 12 months?

Theravance Biopharma lowest stock price was $7.90 and its highest was $20.33 in the past 12 months.

What is Theravance Biopharma’s market cap?

Theravance Biopharma’s market cap is $918.18M.

When is Theravance Biopharma’s upcoming earnings report date?

Theravance Biopharma’s upcoming earnings report date is Mar 02, 2026 which is in 80 days.

How were Theravance Biopharma’s earnings last quarter?

Theravance Biopharma released its earnings results on Nov 10, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.198.

Is Theravance Biopharma overvalued?

According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theravance Biopharma pay dividends?

Theravance Biopharma does not currently pay dividends.

What is Theravance Biopharma’s EPS estimate?

Theravance Biopharma’s EPS estimate is 1.

How many shares outstanding does Theravance Biopharma have?

Theravance Biopharma has 50,672,432 shares outstanding.

What happened to Theravance Biopharma’s price movement after its last earnings report?

Theravance Biopharma reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went up 22.679%.

Which hedge fund is a major shareholder of Theravance Biopharma?

Currently, no hedge funds are holding shares in TBPH

Theravance Biopharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

14.03%

Trailing 12-Months

Asset Growth

16.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of serious diseases. The company primarily operates in the respiratory and immunology sectors, with a portfolio that includes a range of products aimed at addressing unmet medical needs. Theravance Biopharma leverages its expertise in drug development and its proprietary technologies to create therapeutic solutions, with a strong emphasis on improving patient outcomes.

Theravance Biopharma (TBPH) Earnings & Revenues

Historic Earnings Reports

TBPH Company Deck

TBPH Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong financial position with record sales and profitability for YUPELRI, significant progress in ampreloxetine's clinical trials, and upcoming milestone achievements for Trelegy. Despite minor operational challenges, the overall outlook remains positive with a focus on future growth and strategic objectives.View all TBPH earnings summaries

TBPH Stock 12 Month Forecast

Average Price Target

$28.33

▲(60.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","16":"$16","25":"$25","34":"$34","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,16,25,34,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.61,21.33230769230769,23.054615384615385,24.776923076923076,26.49923076923077,28.22153846153846,29.943846153846152,31.666153846153847,33.38846153846154,35.11076923076923,36.83307692307692,38.55538461538461,40.277692307692305,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.61,20.28076923076923,20.951538461538462,21.622307692307693,22.29307692307692,22.963846153846152,23.634615384615383,24.305384615384614,24.976153846153846,25.646923076923073,26.317692307692305,26.988461538461536,27.659230769230767,{"y":28.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.61,19.10153846153846,18.59307692307692,18.084615384615383,17.576153846153847,17.067692307692308,16.55923076923077,16.05076923076923,15.542307692307691,15.033846153846154,14.525384615384615,14.016923076923078,13.508461538461539,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.25,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >